RxDoctor Payments Data

Deborah Schlick, NP

Family · Cape Girardeau, MONPI 1659401933

Payments from drug & device makers

$7,825in general payments, 2019–2025

Across 453 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$804
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$561
  • Bristol Myers Squibb$407
  • Nestle Healthcare Nutrition Inc.$371
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$7,75499%
  • Education$711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,825 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$2,485
Medicare patients
40
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase17$72,208
RelistorMethylnaltrexone Bromide19$52,080
LinzessLinaclotide60$44,758
CreonLipase/Protease/Amylase12$35,253
MovantikNaloxegol Oxalate45$12,979
Colestipol Hcl91$8,930
Dexlansoprazole DrDexlansoprazole38$6,245
ClenpiqSod Picosulf/Mag Ox/Citric Ac20$3,327
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag22$2,737
Pantoprazole Sodium263$2,455
Lactulose22$1,898
Colesevelam Hcl28$1,735
Omeprazole106$1,415
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$1,036
Sucralfate40$837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,098$80,01172 claims
Aimmune Therapeutics, Inc.Zenpep$95$72,20817 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$561$52,08019 claims
Redhill Biopharma Inc.Movantik$23$12,97945 claims
Ferring Pharmaceuticals Inc.Clenpiq$40$3,32720 claims
Braintree Laboratories, Inc.Suflave$188$2,73722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →